Clinical trial
MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes…
NCT00372060 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00372060 |
|---|---|
| Title | MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED) |
| Official title | MK0431 (Sitagliptin) Phase III Clinical Study -Pioglitazone add-on Study for Patients With Type 2 Diabetes Mellitus |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | sitagliptin phosphate, Comparator: sitagliptin phosphate (MK0431), Comparator: pioglitazone, Comparator: placebo (unspecified) |
| Enrollment | 134 |
| Start date | Aug 21, 2006 |
| Primary completion | Feb 5, 2008 |
| Completion | Feb 5, 2008 |
| First posted | Sep 6, 2006 |
| Last update posted | May 12, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: